These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 24977290

  • 1. Identification of N-linked glycosylation and putative O-fucosylation, C-mannosylation sites in plasma derived ADAMTS13.
    Sorvillo N, Kaijen PH, Matsumoto M, Fujimura Y, van der Zwaan C, Verbij FC, Pos W, Fijnheer R, Voorberg J, Meijer AB.
    J Thromb Haemost; 2014 May; 12(5):670-9. PubMed ID: 24977290
    [Abstract] [Full Text] [Related]

  • 2. Identification of glycans on plasma-derived ADAMTS13.
    Verbij FC, Stokhuijzen E, Kaijen PH, van Alphen F, Meijer AB, Voorberg J.
    Blood; 2016 Nov 24; 128(21):e51-e58. PubMed ID: 27574189
    [Abstract] [Full Text] [Related]

  • 3. O-fucosylation is required for ADAMTS13 secretion.
    Ricketts LM, Dlugosz M, Luther KB, Haltiwanger RS, Majerus EM.
    J Biol Chem; 2007 Jun 08; 282(23):17014-23. PubMed ID: 17395589
    [Abstract] [Full Text] [Related]

  • 4. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
    Shelat SG, Ai J, Zheng XL.
    Semin Thromb Hemost; 2005 Dec 08; 31(6):659-72. PubMed ID: 16388417
    [Abstract] [Full Text] [Related]

  • 5. The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice.
    De Cock E, Hermans C, De Raeymaecker J, De Ceunynck K, De Maeyer B, Vandeputte N, Vandenbulcke A, Deckmyn H, Rottensteiner H, De Maeyer M, De Meyer SF, Vanhoorelbeke K.
    J Thromb Haemost; 2015 Feb 08; 13(2):283-92. PubMed ID: 25442981
    [Abstract] [Full Text] [Related]

  • 6. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.
    Lotta LA, Valsecchi C, Pontiggia S, Mancini I, Cannavò A, Artoni A, Mikovic D, Meloni G, Peyvandi F.
    J Thromb Haemost; 2014 Feb 08; 12(3):329-36. PubMed ID: 24354764
    [Abstract] [Full Text] [Related]

  • 7. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.
    Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, van Mourik JA, Fijnheer R, Voorberg J.
    J Thromb Haemost; 2006 Nov 08; 4(11):2355-64. PubMed ID: 16898953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.
    Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D.
    Eur J Pediatr; 2007 Mar 08; 166(3):249-57. PubMed ID: 17187257
    [Abstract] [Full Text] [Related]

  • 10. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
    Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J.
    Thromb Haemost; 2005 Feb 08; 93(2):267-74. PubMed ID: 15711742
    [Abstract] [Full Text] [Related]

  • 11. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR, de Groot R, Scully MA, Crawley JT.
    EBioMedicine; 2015 Aug 08; 2(8):942-52. PubMed ID: 26425702
    [Abstract] [Full Text] [Related]

  • 12. Acquired TTP: ADAMTS13 meets the immune system.
    Verbij FC, Fijnheer R, Voorberg J, Sorvillo N.
    Blood Rev; 2014 Nov 08; 28(6):227-34. PubMed ID: 25213289
    [Abstract] [Full Text] [Related]

  • 13. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
    Casina VC, Hu W, Mao JH, Lu RN, Hanby HA, Pickens B, Kan ZY, Lim WK, Mayne L, Ostertag EM, Kacir S, Siegel DL, Englander SW, Zheng XL.
    Proc Natl Acad Sci U S A; 2015 Aug 04; 112(31):9620-5. PubMed ID: 26203127
    [Abstract] [Full Text] [Related]

  • 14. Conformational activation of ADAMTS13.
    South K, Luken BM, Crawley JT, Phillips R, Thomas M, Collins RF, Deforche L, Vanhoorelbeke K, Lane DA.
    Proc Natl Acad Sci U S A; 2014 Dec 30; 111(52):18578-83. PubMed ID: 25512499
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Jian C, Xiao J, Gong L, Skipwith CG, Jin SY, Kwaan HC, Zheng XL.
    Blood; 2012 Apr 19; 119(16):3836-43. PubMed ID: 22289888
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Yamaguchi Y, Moriki T, Igari A, Nakagawa T, Wada H, Matsumoto M, Fujimura Y, Murata M.
    Thromb Res; 2011 Aug 19; 128(2):169-73. PubMed ID: 21496883
    [Abstract] [Full Text] [Related]

  • 19. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
    Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, Bennett CL, Kwaan HC.
    Haematologica; 2010 Sep 19; 95(9):1555-62. PubMed ID: 20378566
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.